The author's reply

December 2009
Heart;Dec2009, Vol. 95 Issue 24, p16
Academic Journal
An abstract of the author's reply to the article about the trials and pre-hospital treatment with thrombolytic drugs is presented.


Related Articles

  • Postthrombolytic High-Risk Syndrome. Zatuchni, Jacob // Angiology;Aug1988, Vol. 39 Issue 8, p773 

    Presents a letter to the editor about post-thrombolytic high-risk syndrome.

  • Intrapleural Fibrinolytics for Pleural Infection: Optimizing Dosing for Future Trials. Heppler, J. Scott // Mayo Clinic Proceedings;Aug2007, Vol. 82 Issue 8, p1016 

    A letter to the editor is presented in response to the article regarding the use of intrapleural tissue-type plasminogen activator (tPA) for pleural infection.

  • In reply. Levinson, Gary M.; Pennington, Daniel W. // Mayo Clinic Proceedings;Aug2007, Vol. 82 Issue 8, p1016 

    A response by Dr. Thomas J. Romano to a letter to the editor about the article which discusses the use of intrapleural tissue-type plasminogen activator (tPA) for pleural infection is presented.

  • The authors' reply:. Schömig, A.; Sarafoff, N.; Seyfarth, M. // Heart;Jan2010, Vol. 96 Issue 1, p73 

    A letter to the editor is presented in response to the article "Triple antithrombotic management after stent implantation: when and how?," by W. Dewilde and J. Ten Berg.

  • Thrombolytic drugs: If one doesn't work, try another.  // Geriatrics;Aug94, Vol. 49 Issue 8, p58 

    Presents the summary of findings from the study entitled `Differences in Clot Lysis among Patients Demonstrated in vitro with Three Thrombolytic Agents (Tissue-Type Plasminogen Activator, Streptokinase and Urokinase' conducted by D.R. Musselman and others published in the 1994 issue of `American...

  • ERRATUM.  // Angiology;Nov1975, Vol. 26 Issue 10, p758 

    Presents a correction to the article "Thrombolytic Treatment With I.V. Brinase of Advanced Arterial Obliterative Disease of the Limbs" that was published in the previous issue of the journal "Angiology."

  • FDA CLEARS THROMBOLYTIC DRUG FOR PHASE II CLINICAL TRIAL.  // Worldwide Biotech;May2002, Vol. 14 Issue 5, p6 

    Reports on the approval by the U.S. Food and Drug Administration for the testing of British Biotech's novel thrombolytic agent, BB-10153, in heart attack patients.

  • Intraoperative use of thrombolytic agents. Earnshaw, Jonothan J.; Beard, Jonathan // BMJ: British Medical Journal (International Edition);9/11/93, Vol. 307 Issue 6905, p638 

    Focuses on the use of intraoperative thrombolysis in the treatment of acute limb ischaemia. Ischemic neurosensory deficit in patients; Problems associated with streptokinase; Indications of thrombolysis; Need to develop a method to evaluate of intraoperative streptokinase.

  • Eye on the Literature.  // Formulary;May2002, Vol. 37 Issue 5, p230 

    Presents some published studies of interest to drug decision-makers. Effect of thrombolytics to elderly patients; Result of the hypericum perforatum test; Study on the effect of longer thromboembolism prophylaxis medication after surgery.


Read the Article


Sign out of this library

Other Topics